612 related articles for article (PubMed ID: 22420471)
1. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer.
Liu S; Lachapelle J; Leung S; Gao D; Foulkes WD; Nielsen TO
Breast Cancer Res; 2012 Mar; 14(2):R48. PubMed ID: 22420471
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
[TBL] [Abstract][Full Text] [Related]
3. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
4. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.
Ali HR; Provenzano E; Dawson SJ; Blows FM; Liu B; Shah M; Earl HM; Poole CJ; Hiller L; Dunn JA; Bowden SJ; Twelves C; Bartlett JM; Mahmoud SM; Rakha E; Ellis IO; Liu S; Gao D; Nielsen TO; Pharoah PD; Caldas C
Ann Oncol; 2014 Aug; 25(8):1536-43. PubMed ID: 24915873
[TBL] [Abstract][Full Text] [Related]
5. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer.
Chen Z; Chen X; Zhou E; Chen G; Qian K; Wu X; Miao X; Tang Z
PLoS One; 2014; 9(4):e95475. PubMed ID: 24743335
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of T lymphocytes infiltration in breast cancer].
Yu HM; Jiao SC; Yang JL; Wang JD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):199-206. PubMed ID: 23643010
[TBL] [Abstract][Full Text] [Related]
13. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer.
Wang K; Shen T; Siegal GP; Wei S
Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275
[TBL] [Abstract][Full Text] [Related]
14. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer.
Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J
Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.
Mahmoud SM; Paish EC; Powe DG; Macmillan RD; Grainge MJ; Lee AH; Ellis IO; Green AR
J Clin Oncol; 2011 May; 29(15):1949-55. PubMed ID: 21483002
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.
Paulson KG; Iyer JG; Tegeder AR; Thibodeau R; Schelter J; Koba S; Schrama D; Simonson WT; Lemos BD; Byrd DR; Koelle DM; Galloway DA; Leonard JH; Madeleine MM; Argenyi ZB; Disis ML; Becker JC; Cleary MA; Nghiem P
J Clin Oncol; 2011 Apr; 29(12):1539-46. PubMed ID: 21422430
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Machado I; López-Guerrero JA; Scotlandi K; Picci P; Llombart-Bosch A
Virchows Arch; 2018 May; 472(5):815-824. PubMed ID: 29445891
[TBL] [Abstract][Full Text] [Related]
19. T-bet
Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
[TBL] [Abstract][Full Text] [Related]
20. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.
Deschoolmeester V; Baay M; Van Marck E; Weyler J; Vermeulen P; Lardon F; Vermorken JB
BMC Immunol; 2010 Apr; 11():19. PubMed ID: 20385003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
